Meningococcal Disease Treatment Market, By Therapy Type (Antibiotics (Penicillin, Ampicillin, Chloramphenicol, and Ceftriaxone) and (Vaccines (Bivalent, Trivalent, and Tetravalent)), By Route of Administration (Injectable and Oral), By Distribution channe

Meningococcal Disease Treatment Market, By Therapy Type (Antibiotics (Penicillin, Ampicillin, Chloramphenicol, and Ceftriaxone) and (Vaccines (Bivalent, Trivalent, and Tetravalent)), By Route of Administration (Injectable and Oral), By Distribution channel (Hospital Pharmacy, Retail Pharmacy, and Others), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028

Meningococcal infection is a bacterial infection caused by Neisseria meningitidis, also known as meningococcus, a gram-negative bacterium. Meningococcal meningitis is a serious infection of the thin lining that surrounds the brain and spinal cord.
Furthermore, according to the World Health Organization Meningococcal meningitis is observed worldwide but the highest burden of the disease is in the meningitis belt of sub-Saharan Africa, stretching from Senegal in the west to Ethiopia in the east. Around 30,000 cases are still reported each year from that area.
Market Dynamics
The global meningococcal disease treatment market is expected to witness significant growth during the forecast period owing to the increasing prevalence of meningococcal disease. According to the centers for disease control and prevention, there were about 330 total cases of meningococcal disease reported in the U.S. in 2018.
Key features of the study:
This report provides in-depth analysis of the global meningococcal disease treatment market, and provides market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period (2022-2028), considering 2021 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global meningococcal disease treatment market based on the following parameters – company overview, financial performance, product portfolio, market presence, distribution strategies, key developments, strategies, and future plans
Key companies covered as a part of this study are GlaxoSmithKline Plc., Novartis AG, Sanofi Pasteur Inc., Wockhardt Ltd., Kent Pharmaceuticals, Stravencon Limited., F. Hoffmann-La Roche Ltd., Athlone Laboratories, and Pfizer Inc.
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
The global meningococcal disease treatment market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global meningococcal disease treatment market
Detailed Segmentation:
Global Meningococcal Disease Treatment Market, By Therapy Type:
Antibiotics
Penicillin
Ampicillin
Chloramphenicol
Ceftriaxone
Vaccines
Bivalent
Trivalent
Tetravalent
Global Meningococcal Disease Treatment Market, By Route of Administration:
Injectable
Oral
Global Meningococcal Disease Treatment Market, By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Others
Global Meningococcal Disease Treatment Market, By Region:
North America
By Therapy Type
Antibiotics
Penicillin
Ampicillin
Chloramphenicol
Ceftriaxone
Vaccines
Bivalent
Trivalent
Tetravalent
By Route of Administration
Injectable
Oral
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Others
By Country
U.S.
Canada
Latin America
By Therapy Type
Antibiotics
Penicillin
Ampicillin
Chloramphenicol
Ceftriaxone
Vaccines
Bivalent
Trivalent
Tetravalent
By Route of Administration
Injectable
Oral
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Others
By Country
Brazil
Mexico
Argentina
Rest of Latin America
Europe
By Therapy Type
Antibiotics
Penicillin
Ampicillin
Chloramphenicol
Ceftriaxone
Vaccines
Bivalent
Trivalent
Tetravalent
By Route of Administration
Injectable
Oral
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Others
By Country
Germany
U.K.
France
Italy
Spain
Russia
Rest of Europe
Asia Pacific
By Therapy Type
Antibiotics
Penicillin
Ampicillin
Chloramphenicol
Ceftriaxone
Vaccines
Bivalent
Trivalent
Tetravalent
By Route of Administration
Injectable
Oral
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Others
Middle East
By Therapy Type
Antibiotics
Penicillin
Ampicillin
Chloramphenicol
Ceftriaxone
Vaccines
Bivalent
Trivalent
Tetravalent
By Route of Administration
Injectable
Oral
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Others
By Country
GCC
Israel
Rest of Middle East
Africa
By Therapy Type
Antibiotics
Penicillin
Ampicillin
Chloramphenicol
Ceftriaxone
Vaccines
Bivalent
Trivalent
Tetravalent
By Route of Administration
Injectable
Oral
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Others
By Country/Region
South Africa
Central Africa
North Africa
Company Profiles
GlaxoSmithKline Plc.
Company Overview
Product Portfolio
Financial Performance
Recent Highlights
Strategies
Novartis AG
Sanofi Pasteur Inc.
Wockhardt Ltd.
Kent Pharmaceuticals
Stravencon Limited.
F. Hoffmann-La Roche Ltd.
Athlone Laboratories
Pfizer Inc.
“*” marked represents similar segmentation in other categories in the respective section.